# QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

> **NCT03175666** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** avelumab
- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** nab-paclitaxel
- **DRUG:** Lovaza
- **RADIATION:** Stereotactic Body Radiation Therapy
- **BIOLOGICAL:** ALT-803
- **BIOLOGICAL:** ETBX-011
- **BIOLOGICAL:** ETBX-051
- **BIOLOGICAL:** ETBX-061
- **BIOLOGICAL:** GI-4000
- **BIOLOGICAL:** GI-6207
- **BIOLOGICAL:** GI-6301
- **BIOLOGICAL:** haNK

## Key facts

- **NCT ID:** NCT03175666
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2019-01
- **Final completion:** 2021-12-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial not initiated
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03175666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03175666, "QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03175666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*